Vertex Pharmaceuticals Stock Rating Reaffirmed by Wells Fargo & Co. (VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX)‘s stock had its “outperform” rating restated by research analysts at Wells Fargo & Co. in a report released on Tuesday, ARN reports.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 3.60% during mid-day trading on Tuesday, hitting $75.03. 1,639,457 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 52-week low of $38.44 and a 52-week high of $89.96. The stock has a 50-day moving average of $78.21 and a 200-day moving average of $72.45. The company’s market cap is $17.468 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.01. The company had revenue of $222.00 million for the quarter, compared to the consensus estimate of $278.80 million. During the same quarter in the previous year, the company posted $0.13 earnings per share. The company’s revenue for the quarter was down 34.0% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $-2.49 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Needham & Company reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note to investors on Monday, October 21st. They now have a $95.00 price target on the stock. Separately, analysts at UBS AG reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note to investors on Wednesday, October 16th. They now have a $84.00 price target on the stock. Finally, analysts at Barclays cut their price target on shares of Vertex Pharmaceuticals from $95.00 to $92.00 in a research note to investors on Wednesday, October 16th. They now have an “overweight” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $89.68.
In other Vertex Pharmaceuticals news, Director Bruce I. Sachs unloaded 8,300 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $77.06, for a total transaction of $639,598.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.